Answers are grounded in this paper and cite their sources.
Genomic variations' influence on basal pain sensitivity, the likelihood of significant pain and development of chronic pain diseases is the target of current investigations. Catechol‐O‐methyltransferase (COMT) and the μ‐opioid receptor (OPRM1) genes are frequently studied “candidate genes”. This article reviews recent studies of human genetics of pain which implicate polymorphisms in these candidate genes. Associations of COMT and OPRM1 genetic variants were reported with sensitivity to pain, analgesic requirements as well as side effects of pharmacotherapy in either experimental pain settings or in patients suffering from acute or chronic pain. However, attempts to directly link genotypes to pain states remain largely unsuccessful up to date. Studies associating pain or analgesic demands to single nucleotide polymorphisms or haplotypes showed inconsistent results in the majority. There is a need for sufficiently powered studies to adequately address this topic. Innovative techniques and accelerating methodologic advances in the field of genetic analysis will help to reveal associations between genetic variants and pain in the near future.
No takes yet. Share an insight, caveat, or question.
Stamer et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: